AngioDynamics Ownership

ANGO Stock

USD 12.05 0.02 0.17%

Some institutional investors establish a significant position in stocks such as AngioDynamics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of AngioDynamics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Check out Trending Equities. To learn how to invest in AngioDynamics Stock please use our How to Invest in AngioDynamics guide.

AngioDynamics Net Current Assets as percentage of Total Assets are very stable at the moment as compared to the past year. AngioDynamics reported last year Net Current Assets as percentage of Total Assets of 14.36. As of 26th of March 2023, Book Value per Share is likely to grow to 11.27, while Interest Coverage is likely to drop 2.76.

AngioDynamics holds a total of thirty-nine million one hundred thirty-four thousand one hundred outstanding shares. The majority of AngioDynamics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AngioDynamics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AngioDynamics. Please pay attention to any change in the institutional holdings of AngioDynamics as this could imply that something significant has changed or about to change at the company. Also note that nearly three hundred ninety-one thousand three hundred fourty-one invesors are currently shorting AngioDynamics expressing very little confidence in its future performance.

Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Market Capitalization Enterprise Value

AngioDynamics Stock Ownership Analysis

About 96.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.19. Some equities with similar Price to Book (P/B) outperform the market in the long run. AngioDynamics has Price/Earnings To Growth (PEG) ratio of 1.87. The entity recorded a loss per share of 0.83. The firm had not issued any dividends in recent years. AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access and for use in oncology and surgical settings in the United States and internationally. The company was founded in 1988 and is headquartered in Latham, New York. Angiodynamics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 760 people. For more info on AngioDynamics please contact Joseph DeVivo at 518 795 1400 or go to https://www.angiodynamics.com.

Besides selling stocks to institutional investors, AngioDynamics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AngioDynamics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AngioDynamics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

AngioDynamics Quarterly Share Based Compensation

3.35 Million

About 5.0% of AngioDynamics are currently held by insiders. Unlike AngioDynamics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AngioDynamics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

AngioDynamics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. AngioDynamics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that AngioDynamics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial AngioDynamics specific information freely available to individual and institutional investors to make a timely investment decision.

	6th of March 2023 Financial Statements and Exhibits. Regulation FD Disclosure	View
	27th of February 2023 Other Events	View
	10th of February 2023 Unclassified Corporate Event	View

AngioDynamics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as AngioDynamics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AngioDynamics backward and forwards among themselves. AngioDynamics' institutional investor refers to the entity that pools money to purchase AngioDynamics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

	Last Transaction	Type	Shares	Value
Blackrock Inc	2022-12-31	Common Shares	6.7 M	92.5 M
Victory Capital Management Inc	2022-12-31	Common Shares	4.3 M	58.7 M
Polar Capital Holdings Plc	2022-09-30	Common Shares	1.9 M	38.3 M
Vanguard Group Inc	2022-12-31	Common Shares	2.8 M	38.3 M
Dimensional Fund Advisors Lp	2022-12-31	Common Shares	2.7 M	37 M
Loomis Sayles Co L P	2022-09-30	Common Shares	1.4 M	28.4 M
State Street Corp	2022-12-31	Common Shares	2 M	27.7 M
Millennium Management Llc	2022-12-31	Common Shares	2 M	26.9 M
Systematic Financial Management Lp	2022-12-31	Common Shares	1.3 M	17.5 M
Adage Capital Partners Gp Llc	2022-09-30	Common Shares	700 K	14.3 M
Balyasny Asset Management Llc	2022-12-31	Common Shares	1 M	14.3 M

Note, although AngioDynamics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

AngioDynamics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AngioDynamics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AngioDynamics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AngioDynamics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Stephen Trowbridge over a month ago Payment of 555 shares by Stephen Trowbridge of AngioDynamics subject to Rule 16b-3
		Stephen Trowbridge over three months ago Purchase by Stephen Trowbridge of 1083 shares of Angiodynamics
		James Clemmer over three months ago Purchase by James Clemmer of 10000 shares of Angiodynamics
		Helsel Dave over six months ago Sale by Helsel Dave of 5000 shares of Angiodynamics
		Stephen Trowbridge over six months ago Exercise or conversion by Stephen Trowbridge of 14758 shares of Angiodynamics subject to Rule 16b-3
		Dennis Meteny over six months ago Exercise or conversion by Dennis Meteny of 6022 shares of Angiodynamics subject to Rule 16b-3
		Helsel Dave over six months ago Exercise or conversion by Helsel Dave of 6945 shares of Angiodynamics subject to Rule 16b-3
		James Clemmer over six months ago Exercise or conversion by James Clemmer of 25123 shares of Angiodynamics subject to Rule 16b-3
		James Clemmer over six months ago Payment of 8574 shares by James Clemmer of Angiodynamics subject to Rule 16b-3
		Warren Nighan over six months ago Exercise or conversion by Warren Nighan of 3233 shares of Angiodynamics subject to Rule 16b-3
		Warren Nighan over six months ago Payment of 919 shares by Warren Nighan of Angiodynamics subject to Rule 16b-3
		Helsel Dave over six months ago Exercise or conversion by Helsel Dave of 3480 shares of Angiodynamics subject to Rule 16b-3

Be your own money manager

Our tools can tell you how much better you can do entering a position in AngioDynamics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Breakdown Now

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes

All Next

Launch Module

Pair Trading with AngioDynamics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AngioDynamics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AngioDynamics will appreciate offsetting losses from the drop in the long position's value.

Moving together with AngioDynamics

	+	0.78	ABT	Abbott Laboratories		Fiscal Quarter End 31st of March 2023	Pair Corr
	+	0.74	ALHC	Alignment Healthcare LLC		Fiscal Quarter End 31st of March 2023	Pair Corr

Moving against AngioDynamics

-	0.69	ACCD	AccoladeInc	Report 27th of April 2023	Pair Corr
-	0.69	ATEC	Alphatec Holdings	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.61	AMEH	Apollo Medical Holdings	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.42	CPSI	Computer Programs And	Fiscal Quarter End 31st of March 2023	Pair Corr

The ability to find closely correlated positions to AngioDynamics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AngioDynamics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AngioDynamics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AngioDynamics to buy it.

The correlation of AngioDynamics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AngioDynamics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AngioDynamics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AngioDynamics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Check out Trending Equities. To learn how to invest in AngioDynamics Stock please use our How to Invest in AngioDynamics guide. Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for AngioDynamics Stock analysis

When running AngioDynamics price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.

	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation

Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.83)

Revenue Per Share

8.353

Quarterly Revenue Growth

0.091

Return On Assets

(0.0247)

Return On Equity

(0.08)

The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine AngioDynamics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

AngioDynamics Ownership

AngioDynamics Stock Ownership Analysis

AngioDynamics Quarterly Share Based Compensation

3.35 Million

AngioDynamics SEC Filings

AngioDynamics Stock Institutional Investors

AngioDynamics Insider Trading Activities

Be your own money manager

Did you try this?

Run Idea Breakdown Now

Idea Breakdown

Pair Trading with AngioDynamics

Moving together with AngioDynamics

Moving against AngioDynamics

Complementary Tools for AngioDynamics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY